The Government of China had recently granted the "Emergency Use Authorisation" (EUA) for the Covid-19 vaccine developed by YTBH's strategic partner, Shenzhen Kangtai Biological Products Co., Ltd. (“SZKT”)
SZKT has also commenced its vaccination programme in China, with its first batch of vaccination programme of more than 500,000 doses, on 1st June 2021. To date, SZKT's vaccines have been used on millions of China citizen.
With the EUA granted in China, this will pave the way for Malaysia and other countries to start using SZKT vaccines. As soon as some interim results can be gathered within 2 months after the phase 3 trial commenced, accelerated data can be obtained to substantiate the application for EUA in Malaysia & roll out for use thereafter.
Coming back to Yong Tai , the Phase III clinical trial involves 3,000 participants and could last several months or years, as Health director-general Tan Sri Dr Noor Hisham Abdullah mentioned. Prior to COVID-19 pandemic, a vaccine for infectious disease has never been produced in less than several years.
However, there has been an escalation in the approval of vaccines for emergency usage during this pandemic because no country can wait that long.
For example, Pfizer-BioNTech COVID-19 vaccine’s phase III clinical trial began on 27 July 2020 and received approval for emergency usage in November last year.
It will be interesting to see if SZKT's vaccine being granted an approval for emergency usage given the urgent needs for supply of vaccines as well as the earlier emergency usage approval granted by the Chinese government in May.
Thomaszum terutamanya mengusahakan indeks dolar AS dan baru bangun sekitar tengah hari hari ini. Rakan-rakan saya tahu bahawa saya telah membeli stok ini dan bertanya kepada saya, adakah anda tidak gementar dengan apa yang akan berlaku apabila pasaran dibuka hari ini? Saya berkongsi dengannya bahawa sama ada saham atau indeks, ia bergantung terutamanya pada Apa yang "berpotensi", ikuti trendnya. Pedagang perlu membina momentum, dan kita pelabur kecil, hanya mengikuti trend.
Mengenai waktu membeli atau menjual, itu bergantung pada berapa lama atau pendek kitaran yang anda lihat. Dengan Daytrade, dia sudah melompat setinggi tiga kaki dengan sedikit kekacauan. Bukannya dia tidak dapat menahan nafas, tetapi gaya perdagangan. Untuk perubahan atau trend, satu atau dua minggu atau beberapa bulan sudah dianggap panjang. Tetapi jika corak anda adalah arah aliran keseluruhan, melihat susun atur dan pergerakan keseluruhan permainan dari perspektif pemain catur, bahawa adalah perkara lain.
Sudah tentu, kerana keperibadian setiap orang, mod perdagangan, jumlah modal dan faktor lain berbeza, sudut dan corak orang itu secara semula jadi berbeza, jadi tidak ada yang betul atau salah. Selagi kaedah perdagangan anda sesuai dengan anda, anda boleh mencapai matlamat mengumpul modal.boleh.
Oleh itu, pada tahap ini, saya berpendapat bahawa YongTai menjual baru, atau vaksin Malaysia sudah mencukupi, dan tidak ada permintaan, maka anda boleh meletakkan tiket di tangan, yang mungkin tepat dari sudut pandangan anda. , ekuiti persendirian atau perbankan Dari perspektif yang berbeza, kerana visi strategik yang berbeza, kitaran tontonan lebih panjang. Bagi mereka, tahap ini mungkin masih dalam tahap mengumpulkan suara.
Berbanding dengan model Hong Kong, syarikat tersenarai di Malaysia umumnya tidak mempunyai pasukan pelaburan profesional untuk mengintegrasikan sumber dan bekerjasama dengan institusi yang relevan untuk pembangunan yang dirancang. Sebaliknya, mereka hanya bergantung pada operasi membuat keputusan peribadi MD, CEO atau CFO., Itu tidak dapat dielakkan untuk melewatkan penerapan pemaksimalan modal.
Mari lihat bagaimana Yong Tai akan bermain pada akhirnya ...
thomaszum @Trust, saya tidak begitu kenal dengan Kanger, jadi saya hanya boleh membagikannya dengan vaksin.
Terdapat kaedah penyatuan cerdik yang menggunakan antibodi peneutralan orang yang pulih sebagai penanda aras 1. Berbanding dengan antibodi peneutralan yang dihasilkan oleh vaksin, nisbahnya lebih tinggi daripada 1, menunjukkan bahawa kesan yang dihasilkan lebih baik daripada jangkitan semula jadi, iaitu , kesan imun Semakin baik, kesan perlindungan kemungkinan lebih baik.
Berdasarkan pengiraan ini, nisbah antibodi peneutralan Kangtai Bio-KCONVAC adalah 2.7, kedua setelah vaksin Moderna luar negara (4.1), vaksin Pfizer (3.8) dan vaksin Novavax (4.0), dan juga yang terbaik di antara vaksin domestik. Ini bermaksud bahawa sebagai vaksin yang tidak aktif, data KCONVAC sangat menonjol, dan keberkesanannya mungkin lebih tinggi daripada vaksin yang tidak aktif. Saya yakin inilah sebabnya vaksin Kangtai diluluskan untuk penggunaan kecemasan dan menjadi vaksin mahkota baru pertama yang diluluskan untuk penggunaan kecemasan di Guangdong.
Untuk perkara di atas, sila rujuk "YongTai Berhad (7066) vs Ramalan pasaran vaksin-Bahagian 1"
Kedua-dua vaksin sinofarm dan vaksin sinovac termasuk dalam jenis virus yang tidak aktif. Menurut data penyelidikan semasa, nisbah antibodi peneutralan Kangtai Bio-KCONVAC adalah 2.7, yang kini merupakan produk terbaik di antara vaksin yang tidak aktif di China. Mengapa demikian? Kangtai vaksin diluluskan untuk penggunaan kecemasan, menjadi vaksin mahkota baru pertama yang diluluskan untuk penggunaan kecemasan di Guangdong.
Yong Tai’s transformation into a robust cash-flow generation company
*Exclusive distributor for Malaysia, ASEAN and Indian Continental countries
*Committed capacity from Shenzhen Kangtai Biological Products Co. Ltd is 10 million doses per year, with another option of 10 million doses, for a period of 5 + 5 years. If Malaysia faces an oversupply situation, they can sell to other ASEAN countries such as Indonesia, Philippines, Sri Lanka. 20 million doses are insignificant as compared to their respective population
*Vaccines obtained NPRA approval to conduct Phase III Clinical Trial, with the arrival of vaccines expected within the next week
*Currently, all approved vaccines in Malaysia have not completed their Phase III trial. All are under Conditional Market Authorisation (CMA). This includes Pfizer, AstraZeneca and Sinovac.
*Tiong Nam will provide the total logistical services, which include transportation, warehouse space and distribution of the vaccine
*Assuming RM5 GP per dose, it will be RM100 million GP to Yong Tai per annum (20 million doses per year).
*Assuming 24% tax rate and net profits of RM76 million. Based on PE of 10x, company is worth RM760 million market cap or RM0.53/share. This is excluding the profits from its gold venture that is kicking off in July 2021.
*Sources are the Encore Melaka which has been a bleed to the company, will see a restructuring to happen very soon, setting the path for Yong Tai to unlock the value. If this happens, Yong Tai will transform into a company with cash cow businesses (vaccine + gold).
Yongtai operating cash flow negative 40mil. Talk so much also no use. Facts is this company coming to right issue again in very verynear time. Whoever trap inside need to donate some money to spend the management gaji buta
when the price goes up later, then the cunts will go missing, i ponder how much these cunts were paid to make noise here, or so bitter because these cunts didn't collect months earlier when the price was lingering around 0.21 to 0.22, or the cunts were so "smart" to panic sell because these cunts have no holding power, isn't it obvious enough ? i have already told earlier many times, private investors aren't fools, the director that collected earlier aren't fools, the cunts here on the other hand, so obvious *eye rolling*
Private investors sudah cash out la, jangan buat bodoh.. PP harga baru 20sen lebih... no need pump, dumped all on friday siap dah. ni support buat buta je.
well, everyone will know who's the bodoh here soon, and since you claim private investors have dumped, how you know ? mind showing the proof here to everyone instead of claiming bullshit ? it's so easy to spread fake news, and it's so obvious with your case here
for me i doing 2 step 30% keep on hand,60% sell on last week,because this 4 month moving pattern totally understanding,so last week RUN 60% have taken RM 1K profit,and this week waiting add in again...
Let's set a goal together. If this week does not break through and stand above 0.35, let us continue to dig and analyze more in-depth black materials as well, then find out the connections. This will be a very interesting investment activity, isn't it?
Netizens, please help to dig out the partners of their PP cooperation.
These crocodiles are not only greedy, but their eyes are too short and shallow. ^^.
SHARE ACQUISITION AGREEMENT BETWEEN YTB AND TAN YEN YEN FOR THE PROPOSED ACQUISITION OF 70% EQUITY INTEREST OF HUOBI LABUAN LIMITED (“PROPOSED ACQUISITION”);
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
thomaszum
285 posts
Posted by thomaszum > 2021-06-05 21:24 | Report Abuse
https://klse.i3investor.com/blogs/thomaszum/535341.jsp
YongTai Berhad (7066) vs Foresight of the vaccine market - Part 4